Novo Nordisk stock rose 2.5% after announcing a successful oral form of weight loss drug

From Yahoo Finance: 2025-04-22 12:17:00

Novo Nordisk, the Danish drugmaker, saw its stock rise 2.5% as it announced an oral form of its semaglutide GLP-1 weight loss drug. The pill showed patients losing up to 15% of body weight in clinical trials. This news presents both an opportunity and a challenge for the company.

The new GLP-1 pill could make Novo Nordisk even more dominant in the market, but it contains 70 times more semaglutide than injectable Ozempic. This requires a significant increase in production capacity. The company must grow to fully capitalize on this opportunity and maintain its market position.

Investors considering Novo Nordisk stock should note that it wasn’t included in the Motley Fool’s list of the 10 best stocks to buy now. The stocks on this list have historically produced significant returns, outperforming the S&P 500. Don’t miss out on the latest top 10 list by joining Stock Advisor for potential market-crushing returns.



Read more at Yahoo Finance: Why Novo Nordisk Stock Popped Today